{
    "cancer_info": {
        "cancer_name": "Colon Cancer"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Colonoscopy with biopsy",
            "CEA (Carcinoembryonic Antigen) testing",
            "CBC and chemistry profile",
            "CT abdomen/pelvis with IV/oral contrast",
            "CT chest/abdomen/pelvis (contrast-enhanced)",
            "MRI liver (for resectable metastases)",
            "FDG-PET/CT for equivocal findings",
            "Molecular testing: RAS (KRAS/NRAS), BRAF V600E, MSI/MMR status",
            "HER2 amplification testing (IHC/FISH/NGS)",
            "NTRK/RET fusion testing (NGS)",
            "POLE/POLD1 mutation analysis",
            "TMB assessment",
            "Diagnostic laparoscopy for peritoneal disease",
            "Peritoneal Cancer Index (PCI) scoring",
            "Lymph node examination (minimum 12 nodes)",
            "Tumor budding assessment"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage I",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "All",
                    "plan_name": "Surgery only",
                    "plan_details": "Colectomy with complete mesocolic excision",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage II (pMMR/MSS)",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "No high-risk features",
                    "plan_name": "Observation or fluoropyrimidine",
                    "plan_details": "Capecitabine or 5-FU/LV",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage II (pMMR/MSS)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "T4 tumors or high-risk features",
                    "plan_name": "CAPEOX or FOLFOX",
                    "plan_details": "CAPEOX ×3 months or FOLFOX ×6 months",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage III",
            "risk_group": "Low risk (T1-3 N1)",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "All",
                    "plan_name": "CAPEOX or FOLFOX",
                    "plan_details": "CAPEOX ×3 months or FOLFOX ×3-6 months",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage III",
            "risk_group": "High risk (T4 or N2)",
            "treatment_plans": [
                {
                    "treatment_line": "Adjuvant therapy",
                    "patient_subgroup": "All",
                    "plan_name": "CAPEOX or FOLFOX",
                    "plan_details": "CAPEOX ×3-6 months or FOLFOX ×6 months",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (Metastatic)",
            "risk_group": "Resectable metastases",
            "treatment_plans": [
                {
                    "treatment_line": "Perioperative therapy",
                    "patient_subgroup": "pMMR/MSS",
                    "plan_name": "FOLFOX/CAPEOX ± bevacizumab",
                    "plan_details": "4-6 cycles pre/post resection",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Perioperative therapy",
                    "patient_subgroup": "dMMR/MSI-H",
                    "plan_name": "Checkpoint inhibitors",
                    "plan_details": "Nivolumab ± ipilimumab or pembrolizumab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (Metastatic)",
            "risk_group": "Unresectable metastases",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "RAS/BRAF WT left-sided",
                    "plan_name": "Anti-EGFR + chemotherapy",
                    "plan_details": "FOLFOX/CAPEOX + cetuximab/panitumumab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "dMMR/MSI-H",
                    "plan_name": "Checkpoint inhibitors",
                    "plan_details": "Pembrolizumab or nivolumab ± ipilimumab",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Second-line therapy",
                    "patient_subgroup": "BRAF V600E mutant",
                    "plan_name": "Encorafenib + cetuximab",
                    "plan_details": "Targeted combination therapy",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Later-line therapy",
                    "patient_subgroup": "HER2-positive",
                    "plan_name": "HER2-targeted therapy",
                    "plan_details": "Trastuzumab + pertuzumab/tucatinib",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other recommended"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "dMMR/MSI-H: Predicts response to immunotherapy; checkpoint inhibitors preferred in metastatic disease",
            "RAS mutations: Predicts resistance to anti-EGFR therapy; contraindicates cetuximab/panitumumab",
            "BRAF V600E mutation: Poor prognostic factor; indicates need for BRAF/EGFR inhibitor combinations",
            "HER2 amplification: Predicts response to HER2-targeted therapies in later lines",
            "NTRK/RET fusions: Predicts response to targeted inhibitors (larotrectinib/entrectinib for NTRK; selpercatinib for RET)",
            "POLE/POLD1 mutations: Ultra-hypermutated phenotype predicts immunotherapy response when TMB ≥50 mut/Mb",
            "TMB-H (≥10 mut/Mb): May predict pembrolizumab response regardless of MSI status",
            "Primary tumor location (left vs. right): Predictive for anti-EGFR benefit (left-sided tumors show improved survival)"
        ]
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：结肠癌.txt"
}